



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

22 Feb 2021 (#03)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply *ASAP*, but not later than **60 days before the submission date.**

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizek@sun.ac.za

Important Notices

- **[NOT-CA-21-039](#) Notice of Intent to Publish a Funding Opportunity Announcement for Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)**. The National Cancer Institute (NCI) plans to publish a Funding Opportunity Announcement (FOA) as a Request for Applications (RFA) for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will also examine the complex mechanisms and effectors that direct the proliferation and expansion of tumor initiating cells and their progeny to initiate these cancers. The focus of the FOA will be on gastric and gastroesophageal junction (GEJ) adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestation or neoplasia. Each R01 application budget will be limited to \$600,000 direct cost per year for a total of five years.
- **[NOT-NS-21-033](#) Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed)**. The National Institute for Neurological Disorders and Stroke, along with other NIH Institutes and Centers (ICs), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for team-based research projects that develop assays, screens and propose early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and/or validation of pharmacodynamic markers and efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies will also be responsive to this FOA. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in March, 2021 with an expected application due date in April, 2021. NIH intends to fund an estimate of 3-6 awards in fiscal year 2021. Application budgets are limited to a direct costs of \$1.5 million per year including all consortium and subaward costs.
- **[NOT-NS-21-034](#) Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics]**. The National Institute for Neurological Disorders and Stroke, along with other NIH Institutes and Centers (ICs), intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in March, 2021 with an expected application due date in April, 2021.

Upcoming Deadlines

- **[Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries D43](#)** 24 June 2021

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Funding Opportunity Announcements (FOA)

1. Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-19-274](#)

Type: R01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce ("de-implement") the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the Institutes/Centers listed in the FOA.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

2. Global Infectious Disease Research Training Program [D43 Clinical Trial Optional]

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-21-120](#)

Type: D43

Application Due Date: August 3 2021, August 3, 2022, August 3, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research not including HIV/AIDS. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and professional development.

Budget: Application budgets are limited to \$230,000 per year for new awards and \$276,000 per year for renewal awards (total direct costs). The maximum project period allowed is 5 years.

3. Minor Use Minor Species Development of Drugs (R01)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR 21-179](#)

Type: R01

Application Due Date: July 30, 2021; February 4, 2022; July 29, 2022; February 3, 2023; July 28, 2023; February 2, 2024. 11:59 PM Eastern Time on the application due date.

Funding Opportunity Announcement: This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS).

The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs.

Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants.

- The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species "designation" granted by FDA/CVM's Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516.

- FDA/CVM's Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and include future recommended support for 2 additional years contingent upon annual appropriations, availability of funding and satisfactory awardee performance. FDA/CVM intends to fund up to \$500,000 yearly for fiscal year (FY) 2022, FY2023 and FY2024 in support of this grant program. It is anticipated that up to 6 awards will be made per FY, not to exceed \$250,000 in total costs (direct plus indirect), per award.

4. Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-21-007](#)

Type: R61/R33

Application Due Date: June 30, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: To support the design of novel tuberculosis (TB) vaccine candidates that exploit innovative approaches and their advancement into preclinical animal model testing. This funding opportunity will use a milestone driven, biphasic award mechanism to fund high risk/exploratory research. Transition to the second phase depends on the successful completion of milestones.

Budget: NIAID intends to commit \$4,000,000 in FY 2022 to fund up to 8 awards. Future year amounts will depend on annual appropriations. Application budgets are limited to \$300,000 in direct costs per year in the R61 phase and \$600,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project.

5. Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-CA-21-030](#)

Type: U01

Application Due Date: June 02, 2021. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

Budget: NCI intends to commit \$4.0 million to support up to six awards in FY2022. Applicants may request up to \$475,000 in direct costs per year. The proposed project period must not exceed 5 years.

6. Dermal Physiologically-based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-solvent following the Application of Generic Dermatological Products (U01)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-21-019](#)

Type: U01

Application Due Date: Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall objective of this funding opportunity is to develop an enhanced mechanistic PBPK model for generic dermatological drug products by taking account the absorption and evaporation of vehicle/co-solvent simultaneously and implementing the effect of these two dynamic processes on the permeation of drug molecule through skin. The developed model will be utilized to inform decisions on generic dermatological product development, to enhance the understanding of the effect of metamorphosis of dermatological drug products on skin absorption, and to predict the local and systemic exposure of drug molecule following topical application of dermatological drug products.

Budget: It is anticipated that up to two awards will be made, not to exceed \$250,000 in total costs (direct plus indirect), per award, per year. The scope of the proposed project should determine the project period. The maximum project period is TWO (2) years.

7. Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01) Clinical Trials Not Required

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-FD-22-001](#)

Type: R01

Application Due Date: February 15, 2022; February 13, 2024: by 11:59 PM Eastern Time.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support efficient and innovative natural history studies that advance medical product development in rare diseases/conditions with unmet needs. Through the support of natural history studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and facilitate rare disease product development.

Budget: Prospective Natural History Studies - Application budgets need to reflect the actual needs of the proposed project and should not exceed \$400 000 total costs (direct and indirect) per year and maximum of 4 years.

Retrospective Natural History Studies or Survey Studies - Application budgets need to reflect the actual needs of the proposed project and should not exceed \$150 000 total costs (direct and indirect) per year and maximum of 2 years.

For those studies with an expected duration of more than 1 year, a second, third, or fourth year of noncompetitive continuation of support will depend on the following factors: (1) Performance during the preceding year; (2) compliance with regulatory requirements, as applicable; and (3) availability of Federal funds.

8. Tobacco Regulatory Science (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-OD-21-002](#)

Type: R01

Application Due Date: July 14, 2021, February 15, 2022, July 14, 2022, February 14, 2023. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement:

Budget: NIH, via support from the FDA Center for Tobacco products (CTP), intends to fund up to 8 R01s, corresponding to a total of up to \$4 million, for fiscal year 2021. Future year amounts will depend on availability of funds. Application budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

9. Fogarty Global Trauma and Injury Research Training Program (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-TW-21-003](#)

Type: D43

Application Due Date: April 16, 2021 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The overall objective of this Funding Opportunity Announcement (FOA) is to strengthen trauma and injury research capacity at academic institutions in low- and middle-income countries (LMICs) through support for research training programs.

- Research training and capacity training programs should:
- Provide in depth training in research design, methods, and analytic techniques appropriate for trauma and injury research;
- Support trainees to conduct mentored research using state-of-the-art methods;
- Provide training in scientific presentation and publication;
- Support trainees to obtain advanced degrees (Master's or Ph.D.) in trauma and injury research; and
- Support research faculty/mentors to strengthen trauma and injury research capacity at LMIC institutions, and to contribute to national and global trauma and injury research initiatives and networks.
- This Funding Opportunity Announcement (FOA) allows trainees to propose to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Budget: FIC and partner [components](#) intend to commit an estimated total of \$1.9 million for FY2022. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request up to \$270,000 per year in total costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105